TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25681041

Group type: EXPERIMENTAL
Intervention: Bonfils intubation fibrescope (BIF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tube introducer-assisted left molar (LM) laryngoscopy
Number of subjects: 120
Study: 23232002

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) prophylaxis for 96 weeks
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Placebo for 96 weeks
Number of subjects: 1351
Study: 20937043

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 45
Study: 18764913

Group type: EXPERIMENTAL
Intervention: Intranasal oxygen therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intranasal air
Number of subjects: 30
Study: 17152347

Group type: COMPARATOR
Intervention: Rifampicin (600 mg orally once per day for 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg orally once per day for 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 12
Study: 12603451

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study: 15231966

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.3 mg/kg once daily)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 10195359

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg given once daily for 2 weeks
Number of subjects: 201
Study: 8995922

Group type: EXPERIMENTAL
Intervention: Therapy for TMD (various interventions, specifics not provided)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Uncontrolled observations (case series, case reports, etc.)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Evidence-based treatment approaches
Number of subjects: 1200
Study: 2357109

Group type: EXPERIMENTAL
Intervention: Psychiatric liaison nurse specialist consultation
Number of subjects: 107

Group type: COMPARATOR
Intervention: No consultation (control group)
Number of subjects: 107
Study: 307358

Group type: EXPERIMENTAL
Intervention: Surgical treatment (saphenous-vein bypass surgery)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Medical treatment (propranolol therapy)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 130
Study: 29734923

Group type: EXPERIMENTAL
Intervention: Virtual reality group (VRG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tutor-administered group (TAG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-listed control group (CG)
Number of subjects: 90
Study: 31058772

Group type: EXPERIMENTAL
Intervention: Enhanced Protein Diet (EPD) with protein‐energy ratio 4 g/100 calories
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD) with protein‐energy ratio 3 g/100 calories
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enhanced Protein Diet (EPD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard Protein Diet (SPD)
Number of subjects: 36
Study: 28498927

Group type: EXPERIMENTAL
Intervention: Carbetocin as bolus (100 mcg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Carbetocin as short infusion (100 mcg)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups (bolus and short infusion)
Number of subjects: 140
Study: 25476156

Group type: COMPARATOR
Intervention: Standard dose radiography
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: 33% reduced dose radiography
Number of subjects: 288
Study: 23970131

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (six times per week) in the daily trial
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis (six times per week) in the nocturnal trial
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional therapy (three times per week) in the daily trial
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional therapy (three times per week) in the nocturnal trial
Number of subjects: 332
Study: 21097567

Group type: EXPERIMENTAL
Intervention: Tele-Airway Management System (TAMS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: On-scene directed (OSD) group
Number of subjects: 25
Study: 19167958

Group type: EXPERIMENTAL
Intervention: Low-glycemic index (GI) diet
Number of subjects: 23
Study: 17079787

Group type: EXPERIMENTAL
Intervention: Point-of-care testing (POCT) for influenza
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard testing (ST) for influenza
Number of subjects: 700
Study: 15271701

Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg/kg/h continuous infusion)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ondansetron (0.1 mg/kg IV every 6 h)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Midazolam and Ondansetron
Number of subjects: 200
Study: 11578261

Group type: EXPERIMENTAL
Intervention: Single atrial cannulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single atrial cannulation and intraoperative zero fluid balance hemofiltration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bi-caval cannulation
Number of subjects: 120
Study: 9228472

Group type: EXPERIMENTAL
Intervention: Fluconazole 800 mg intravenous loading dose, then 400 mg daily for four weeks (intravenous for at least 10 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amphotericin B 0.6 mg/kg/day (cumulative dose 8 mg/kg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 106
Study: 7962885

Group type: EXPERIMENTAL
Intervention: Cue Exposure (CE) treatment with 400 min exposure to the sight and smell of preferred drinks over 10 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Relaxation Control (RC) treatment with 20 min exposure to alcohol cues
Number of subjects: 35
Study: 29596904

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 19
Study: 26908565

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 24074849

Group type: EXPERIMENTAL
Intervention: Varenicline (placebo-controlled)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23733031

Group type: EXPERIMENTAL
Intervention: Dietary flaxseed supplementation (30 g total, in 2 muffins and 1 slice of bread daily)
Number of subjects: 32
Study: 20626325

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 600 mg/day) with cisplatin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: salicylate (300 mg/day) with cisplatin
Number of subjects: 54

Group type: COMPARATOR
Intervention: cisplatin
Number of subjects: 54
Study: 19128716

Group type: EXPERIMENTAL
Intervention: Swaystar transducers
Number of subjects: 9

Group type: COMPARATOR
Intervention: Computerized dynamic posturography (CDP)
Number of subjects: 9
Study: 17162430

Group type: COMPARATOR
Intervention: Calcium Acetate
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sevelamer Hydrochloride
Number of subjects: 70
Study: 12830065

Group type: EXPERIMENTAL
Intervention: Heparin autotransfusion (group H)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Citrate autotransfusion (group C)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (N)
Number of subjects: 144
Study: 10980459

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 0
Study: 8871794

Group type: EXPERIMENTAL
Intervention: Individual behavioural-cognitive therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 27
Study: 1627968

Group type: COMPARATOR
Intervention: Buspirone (20-100 mg/day for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Verapamil (40-100 mg/day for 3 weeks)
Number of subjects: 22
Study: 6585372

Group type: EXPERIMENTAL
Intervention: Double headed toothbrush
Number of subjects: 39

Group type: COMPARATOR
Intervention: Single headed toothbrush with modified Bass technique
Number of subjects: 39

Group type: COMPARATOR
Intervention: Single headed toothbrush with modified Bass and roll techniques
Number of subjects: 39
Study: 31320353

Group type: EXPERIMENTAL
Intervention: Personalised adherence intervention (XPAND)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 24
Study: 29346503

Group type: EXPERIMENTAL
Intervention: High p53β expression
Number of subjects: 266

Group type: COMPARATOR
Intervention: p53 wild-type
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: p53β transfected 786-O and CAKi-1 cells
Number of subjects: 266
Study: 27184664

Group type: EXPERIMENTAL
Intervention: Cardio First Angel™ CPR feedback device
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard manual CPR
Number of subjects: 80
Study: 25413974

Group type: EXPERIMENTAL
Intervention: Safeguarding Children Assessment and Analysis Framework (SAAF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 6
Study: 22217004

Group type: EXPERIMENTAL
Intervention: Partial resection of the distal sac and suture ligation at the neck (Group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Suture ligation at the neck (Group II)
Number of subjects: 50
Study: 20868800

Group type: EXPERIMENTAL
Intervention: Ischemic conditioning of the gastric conduit (laparoscopic gastrolysis)
Number of subjects: 19
Study: 18081861

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flap operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Protein Derivatives (EMD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (flap operation)
Number of subjects: 0
Study: 16055826

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Informed consent procedure
Number of subjects: 20
Study: 12108557

Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Involuntary outpatient commitment (OPC) combined with frequent outpatient mental health services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case managers' verbal reminders about consequences of nonadherence to treatment
Number of subjects: 0
Study: 10663897

Group type: EXPERIMENTAL
Intervention: Cinedefecography evidence of difficult evacuation (Group 1)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cinedefecography evidence of difficult evacuation with rectocele (Group 1)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cinedefecography evidence of difficult evacuation with intussusception (Group 1)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment for patients with rectocele (Group 1)
Number of subjects: 185
Study: 8578808

Group type: EXPERIMENTAL
Intervention: RRV‐TV (rhesus tetravalent rotavirus vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRV‐S1 (serotype 1 monovalent rotavirus vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRV‐TV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRV‐S1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RRV vaccines
Number of subjects: 0
Study: 2190565

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 414613

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 mg sublingually)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30916035

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control ventilation
Number of subjects: 110
Study: 29781640

Group type: EXPERIMENTAL
Intervention: Working memory depletion task
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 24
Study: 26578353

Group type: EXPERIMENTAL
Intervention: Active SMC with sulphadoxine-pyrimethamine and amodiaquine plus AL for case management
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo SMC plus AL for case management
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Long-acting ACT (dihydroartemisinin-piperaquine, DP) for case management
Number of subjects: 2400
Study: 25266831

Group type: EXPERIMENTAL
Intervention: Contact lens aphakic correction
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intraocular lens (IOL) placement
Number of subjects: 114
Study: 22192640

Group type: EXPERIMENTAL
Intervention: TCI remifentanil
Number of subjects: 36

Group type: COMPARATOR
Intervention: TCI propofol
Number of subjects: 36
Study: 20946141

Group type: EXPERIMENTAL
Intervention: Australian Medical Sheepskin (AMS) as a layer on the mattress, applied within 48 hours after admission, alongside usual care.
Number of subjects: 588

Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Australian Medical Sheepskin (AMS) with adjustment for Braden risk score, age, and gender.
Number of subjects: 588
Study: 17293228

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor (GM-CSF) 250 microg/m2, subcutaneous injection, 3 times a week
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 16573802

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily plus Aspirin 325 mg once daily (E40 b.d. + A325)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily plus Rofecoxib 25 mg once daily (E40 b.d. + R25)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily (E40 b.d.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily (R25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (Esomeprazole 40 mg b.d. and Rofecoxib 25 mg once daily)
Number of subjects: 45
Study: 12796713

Group type: EXPERIMENTAL
Intervention: 6.72% sodium lactate infusion at a rate of 50 micro mol. kg‐1. min‐1 for 20 minutes, then reduced to 30 micro mol. kg‐1. min‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1.4% sodium bicarbonate infusion
Number of subjects: 8
Study: 10352333

Group type: EXPERIMENTAL
Intervention: 250 mg aspirin daily for 7 days
Number of subjects: 20
Study: 7588683

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (artificially sweetened, coloured water), mean 1.49 L consumed, mean 1.02 L available after accounting for stomach retention and urination
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (artificially sweetened, coloured water)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 8
Study: 1742818

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg‐1 and midazolam 0.2 mg.kg‐1 (Group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg‐1 and midazolam 0.4 mg.kg‐1 (Group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Higher dose of midazolam (0.4 mg.kg‐1)
Number of subjects: 20
Study: 7056975

Group type: EXPERIMENTAL
Intervention: Combination therapy consisting of estrogen, fluoride, and calcium
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fluoride and calcium without estrogen (Control)
Number of subjects: 9
Study: 31479009

Group type: EXPERIMENTAL
Intervention: ACLR athletes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Uninjured controls
Number of subjects: 42
Study: 28965476

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 35
Study: 27880977

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 100
Study: 25840501

Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TELE)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Home-visit rehabilitation (VISIT)
Number of subjects: 197
Study: 24175566

Group type: EXPERIMENTAL
Intervention: Castrated prostatic cancer patients (group III)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Non-castrated prostatic cancer patients (group II)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Non-prostatic cancer patients (group I)
Number of subjects: 247
Study: 21128876

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-substance-dependent, non-homeless)
Number of subjects: 20
Study: 19150530

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study: 16762992

Group type: EXPERIMENTAL
Intervention: Normal weight adolescents
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: At risk for overweight adolescents
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Overweight adolescents
Number of subjects: 215
Study: 14725954

Group type: EXPERIMENTAL
Intervention: Classroom-centered (CC) intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Family-school partnership (FSP) intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (standard educational setting)
Number of subjects: 80
Study: 10873409

Group type: EXPERIMENTAL
Intervention: LEETZ followed by laser vaporization
Number of subjects: 426

Group type: COMPARATOR
Intervention: LEETZ alone
Number of subjects: 426
Study: 9279674

Group type: EXPERIMENTAL
Intervention: Diclofenac eyedrops
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 1650108

Group type: EXPERIMENTAL
Intervention: Transcranial electric treatment (TET) using a combination of direct current and pulse current at a frequency of 70-80 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6406397

Group type: EXPERIMENTAL
Intervention: Split-course pelvic irradiation (10 fractions of 250 rad each, total 5000 rad)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Continuous pelvic irradiation (30 fractions of 170 rad each, total 5100 rad)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Both groups followed by intracavitary brachytherapy (3000 rad at point A) or external boost (1600 rad) if brachytherapy not possible
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Overall tumor control at two years: 81% for Stage II-B, 67% for III-A, 53% for Stage III-B, 32% for Stage IV-A
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Overall two-year survival: 70% for Stage II-B, 58% for III-A, 46% for III-B, 23% for IV-A
Number of subjects: 287
Study: 31776362

Group type: EXPERIMENTAL
Intervention: Strict volume control monitored by bioimpedance spectroscopy (BIS)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Time-averaged normohydration
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Time-averaged overhydration (TA-OH/ECW)
Number of subjects: 151
Study: 28318687

Group type: EXPERIMENTAL
Intervention: EVEN group (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: UNEVEN group (n=7)
Number of subjects: 14
Study: 26237453

Group type: EXPERIMENTAL
Intervention: PAPD plus SRP
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham treatment plus SRP
Number of subjects: 24
Study: 22945709

Group type: EXPERIMENTAL
Intervention: Transpositional flap (TF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 20
Study: 20299535

Group type: EXPERIMENTAL
Intervention: Wake up and breathe protocol (interrupts and reduces sedative exposure)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Wake up and breathe protocol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sedation per usual care plus daily SBTs (control)
Number of subjects: 180
Study: 18413707

Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretations
Number of subjects: 100
Study: 16080072

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg followed by 50 mg intravenously twice daily)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Vancomycin (1 g intravenously twice daily) plus Aztreonam (2 g intravenously twice daily)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Vancomycin-aztreonam
Number of subjects: 1116
Study: 12439772

Group type: EXPERIMENTAL
Intervention: Eccentric training (six sets of six eccentric contractions at 120% of one maximal concentric repetition, performed four times a week for four weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 14
Study: 10473957

Group type: EXPERIMENTAL
Intervention: 0.05% retinaldehyde
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study: 8644912

Group type: EXPERIMENTAL
Intervention: Magnetic bead antigen‐capture enzyme linked immunoassay (MBAC‐EIA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger individuals (5‐14 years of age)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older individuals (greater than 14 years of age)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study: 1922662

Group type: EXPERIMENTAL
Intervention: Alternate treatment with Prednisone (Polfa) and Decaris (Richter)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prednisone (Polfa) exclusively
Number of subjects: 18
Study: 6823476

Group type: EXPERIMENTAL
Intervention: Rotation-advancement repairs
Number of subjects: 35

Group type: COMPARATOR
Intervention: Triangular repairs
Number of subjects: 35
Study: 31324233

Group type: EXPERIMENTAL
Intervention: Online HIV intervention services
Number of subjects: 1100
Study: 29650208

Group type: EXPERIMENTAL
Intervention: Walking and talking intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study: 26903314

Group type: EXPERIMENTAL
Intervention: QAMS-containing acrylic disks
Number of subjects: 32

Group type: COMPARATOR
Intervention: QAMS-free control disks
Number of subjects: 32